Clinicopathological Parameters of HER2 Low Breast Cancers
NCT ID: NCT06433804
Last Updated: 2024-05-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
70 participants
OBSERVATIONAL
2022-01-01
2024-02-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This study was performed in line with STROCSS criteria. The following clinicopathological data was retrieved from the histopathological records- age, tumor size, nodal involvement, lymphovascular/ perineural invasion, and Bloom Richardson grading.
Routine histopathological processing was done followed by immunohistochemical analysis for ER, PR, HER2, Ki67 and AR. All the cases were categorised into Luminal A, B, Her2 enriched and triple-negative breast cancer based on the surrogate molecular classification. Further, all the cases were categorised into HER2 negative (no staining or incomplete weak membrane staining in ≤10% tumor cells), HER2 3+ (complete membranous staining) and HER2 low (1-2+ staining without amplification on ISH) based on consensus of two pathology consultants. The present study aims to evaluate the clinicopathological parameters of the HER2 low breast cancers.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Comparative Expression of ER,PR and HER2/Neu in Initial and Recurrent Breast Cancer.
NCT07056205
Tumor Characteristics and Survival Rate of HER2-Low Breast Cancer Patients
NCT05754047
NIS Study Determining Prevalence of HER2-low in Metastatic Breast Cancer Patients
NCT06131424
Implementation of Solid Digital PCR to Support Gold-standard Methods for Evaluation of HER2 Amplification Status: Focus on HER2-low Subtype
NCT06813456
HER2-positive Breast Cancer Registry
NCT06603597
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
HER2 low
HER2 IHC
Immunohistochemistry for HER2
HER2 negative
HER2 IHC
Immunohistochemistry for HER2
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
HER2 IHC
Immunohistochemistry for HER2
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Vardhman Mahavir Medical College And Safdarjung Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
SANA AHUJA
ASSISTANT PROFESSOR
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
VMMC SJH
New Delhi, , India
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CC-229
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.